Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2010, Article ID 672137, 3 pages
http://dx.doi.org/10.1155/2010/672137
Clinical Study

Treatment Outcome of Acute Promyelocytic Leukemia with Modified Aida Protocol

Hematology and Hemotherapy Center, University of Campinas, SP, Rua Carlos Chagas 480, Campinas 13083-970, Brazil

Received 29 January 2010; Accepted 17 March 2010

Academic Editor: Jesus Fernando San Miguel

Copyright © 2010 Kátia B. Barbosa Pagnano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We analyzed the outcome of a series of 19 newly diagnosed patients with acute promyelocytic leukemia treated with AIDA modified protocol, using mitoxantrone in place of idarubicin. Eleven patients achieved morphologic CR (58%). The remaining 8 patients had induction failure due to death during induction. Ten of eleven patients in CR achieved molecular remission after induction therapy and all the 8 patients had molecular remission after consolidation. Eight patients completed the three consolidation courses as scheduled and then proceeded to maintenance therapy. After a median follow up of 52 months, no molecular or hematological relapse has occurred. The 4-year disease-free survival is 82%. The study showed the antileukemic efficacy of mitoxantrone and that it could be used as a reasonable option in anthracycline-based strategies in APL.